Primary Biliary Cholangitis Market 2027 By Treatment Type, Distribution Channel and Geography | The Insight Partners

Primary Biliary Cholangitis Market to 2027 - Global Analysis and Forecasts By Treatment Type (Drugs, Liver Transplantation); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00005562 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Primary biliary cholangitis (PBC) previously known as Primary Biliary Cirrhosis, is a chronic liver disease that originates in the bile ducts. The bile ducts are damaged, as in primary biliary cirrhosis and harmful substances may build up in liver, which leads to irreversible scarring of liver tissue. PBC is considered as autoimmune disease in which body turn against own cells. The primary biliary cholangitis develop slowly.

MARKET DYNAMICS
The primary biliary cholangitis market is expected to grow in coming years owing to factors such as increase in research and development activities for development of medication, increasing number of patients suffering from primary biliary cholangitis and others. On the other hand increase in approvals of drugs to treat PBC by Food and Drug Administration (FDA) is likely to offer opportunities in market.

MARKET SCOPE
The "Global Primary Biliary Cholangitis Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of primary biliary cholangitis market with detailed market segmentation by treatment type, end user and geography. The global primary biliary cholangitis market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading primary biliary cholangitis market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global primary biliary cholangitis market is segmented on the basis of treatment type and end user. Based on treatment type, the market is segmented as drugs and liver transplantation. The drug segment is further classified into symptomatic relief treatment, ursodeoxycholic (UDCA) and obeticholic acid (ocaliva). Based on end user the primary biliary cholangitis market is segmented hospital pharmacies, retail pharmacies and online pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global primary biliary cholangitis market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The primary biliary cholangitis market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting primary biliary cholangitis market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the primary biliary cholangitis market in these regions.

MARKET PLAYERS
The reports cover key developments in the primary biliary cholangitis market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from primary biliary cholangitis market are anticipated to lucrative growth opportunities in the future with the rising demand for primary biliary cholangitis in the global market. Below mentioned is the list of few companies engaged in the primary biliary cholangitis market.

The report also includes the profiles of key primary biliary cholangitis market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Zydus Pharmaceuticals, Inc.
  • Tagi Pharma, Inc.
  • Intercept Pharmaceuticals, Inc.
  • ALLERGAN
  • Amneal Pharmaceuticals LLC
  • Mylan N.V
  • Lannett
  • Hikma Pharmaceuticals PLC
  • Gemini Pharmaceuticals.
  • Bristol-Myers Squibb Company
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Primary Biliary Cholangitis Market - By Treatment Type
1.3.2 Primary Biliary Cholangitis Market - By Distribution Channel
1.3.3 Primary Biliary Cholangitis Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PRIMARY BILIARY CHOLANGITIS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PRIMARY BILIARY CHOLANGITIS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PRIMARY BILIARY CHOLANGITIS MARKET - GLOBAL MARKET ANALYSIS
6.1. PRIMARY BILIARY CHOLANGITIS - GLOBAL MARKET OVERVIEW
6.2. PRIMARY BILIARY CHOLANGITIS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. PRIMARY BILIARY CHOLANGITIS MARKET - REVENUE AND FORECASTS TO 2027 - TREATMENT TYPE
7.1. OVERVIEW
7.2. TREATMENT TYPE MARKET FORECASTS AND ANALYSIS
7.3. DRUGS
7.3.1. Overview
7.3.2. Drugs Market Forecast and Analysis
7.3.3. Symptomatic Relief Treatment Market
7.3.3.1. Overview
7.3.3.2. Symptomatic Relief Treatment Market Forecast and Analysis
7.3.4. Ursodeoxycholic Acid (UDCA) Market
7.3.4.1. Overview
7.3.4.2. Ursodeoxycholic Acid (UDCA) Market Forecast and Analysis
7.3.5. Obeticholic Acid (Ocaliva) Market
7.3.5.1. Overview
7.3.5.2. Obeticholic Acid (Ocaliva) Market Forecast and Analysis
7.4. LIVER TRANSPLANTATION
7.4.1. Overview
7.4.2. Liver Transplantation Market Forecast and Analysis
8. PRIMARY BILIARY CHOLANGITIS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. PRIMARY BILIARY CHOLANGITIS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Primary Biliary Cholangitis Market Overview
9.1.2 North America Primary Biliary Cholangitis Market Forecasts and Analysis
9.1.3 North America Primary Biliary Cholangitis Market Forecasts and Analysis - By Treatment Type
9.1.4 North America Primary Biliary Cholangitis Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Primary Biliary Cholangitis Market Forecasts and Analysis - By Countries
9.1.5.1 United States Primary Biliary Cholangitis Market
9.1.5.1.1 United States Primary Biliary Cholangitis Market by Treatment Type
9.1.5.1.2 United States Primary Biliary Cholangitis Market by Distribution Channel
9.1.5.2 Canada Primary Biliary Cholangitis Market
9.1.5.2.1 Canada Primary Biliary Cholangitis Market by Treatment Type
9.1.5.2.2 Canada Primary Biliary Cholangitis Market by Distribution Channel
9.1.5.3 Mexico Primary Biliary Cholangitis Market
9.1.5.3.1 Mexico Primary Biliary Cholangitis Market by Treatment Type
9.1.5.3.2 Mexico Primary Biliary Cholangitis Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Primary Biliary Cholangitis Market Overview
9.2.2 Europe Primary Biliary Cholangitis Market Forecasts and Analysis
9.2.3 Europe Primary Biliary Cholangitis Market Forecasts and Analysis - By Treatment Type
9.2.4 Europe Primary Biliary Cholangitis Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Primary Biliary Cholangitis Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Primary Biliary Cholangitis Market
9.2.5.1.1 Germany Primary Biliary Cholangitis Market by Treatment Type
9.2.5.1.2 Germany Primary Biliary Cholangitis Market by Distribution Channel
9.2.5.2 France Primary Biliary Cholangitis Market
9.2.5.2.1 France Primary Biliary Cholangitis Market by Treatment Type
9.2.5.2.2 France Primary Biliary Cholangitis Market by Distribution Channel
9.2.5.3 Italy Primary Biliary Cholangitis Market
9.2.5.3.1 Italy Primary Biliary Cholangitis Market by Treatment Type
9.2.5.3.2 Italy Primary Biliary Cholangitis Market by Distribution Channel
9.2.5.4 Spain Primary Biliary Cholangitis Market
9.2.5.4.1 Spain Primary Biliary Cholangitis Market by Treatment Type
9.2.5.4.2 Spain Primary Biliary Cholangitis Market by Distribution Channel
9.2.5.5 United Kingdom Primary Biliary Cholangitis Market
9.2.5.5.1 United Kingdom Primary Biliary Cholangitis Market by Treatment Type
9.2.5.5.2 United Kingdom Primary Biliary Cholangitis Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Primary Biliary Cholangitis Market Overview
9.3.2 Asia-Pacific Primary Biliary Cholangitis Market Forecasts and Analysis
9.3.3 Asia-Pacific Primary Biliary Cholangitis Market Forecasts and Analysis - By Treatment Type
9.3.4 Asia-Pacific Primary Biliary Cholangitis Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Primary Biliary Cholangitis Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Primary Biliary Cholangitis Market
9.3.5.1.1 Australia Primary Biliary Cholangitis Market by Treatment Type
9.3.5.1.2 Australia Primary Biliary Cholangitis Market by Distribution Channel
9.3.5.2 China Primary Biliary Cholangitis Market
9.3.5.2.1 China Primary Biliary Cholangitis Market by Treatment Type
9.3.5.2.2 China Primary Biliary Cholangitis Market by Distribution Channel
9.3.5.3 India Primary Biliary Cholangitis Market
9.3.5.3.1 India Primary Biliary Cholangitis Market by Treatment Type
9.3.5.3.2 India Primary Biliary Cholangitis Market by Distribution Channel
9.3.5.4 Japan Primary Biliary Cholangitis Market
9.3.5.4.1 Japan Primary Biliary Cholangitis Market by Treatment Type
9.3.5.4.2 Japan Primary Biliary Cholangitis Market by Distribution Channel
9.3.5.5 South Korea Primary Biliary Cholangitis Market
9.3.5.5.1 South Korea Primary Biliary Cholangitis Market by Treatment Type
9.3.5.5.2 South Korea Primary Biliary Cholangitis Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Primary Biliary Cholangitis Market Overview
9.4.2 Middle East and Africa Primary Biliary Cholangitis Market Forecasts and Analysis
9.4.3 Middle East and Africa Primary Biliary Cholangitis Market Forecasts and Analysis - By Treatment Type
9.4.4 Middle East and Africa Primary Biliary Cholangitis Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Primary Biliary Cholangitis Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Primary Biliary Cholangitis Market
9.4.5.1.1 South Africa Primary Biliary Cholangitis Market by Treatment Type
9.4.5.1.2 South Africa Primary Biliary Cholangitis Market by Distribution Channel
9.4.5.2 Saudi Arabia Primary Biliary Cholangitis Market
9.4.5.2.1 Saudi Arabia Primary Biliary Cholangitis Market by Treatment Type
9.4.5.2.2 Saudi Arabia Primary Biliary Cholangitis Market by Distribution Channel
9.4.5.3 U.A.E Primary Biliary Cholangitis Market
9.4.5.3.1 U.A.E Primary Biliary Cholangitis Market by Treatment Type
9.4.5.3.2 U.A.E Primary Biliary Cholangitis Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Primary Biliary Cholangitis Market Overview
9.5.2 South and Central America Primary Biliary Cholangitis Market Forecasts and Analysis
9.5.3 South and Central America Primary Biliary Cholangitis Market Forecasts and Analysis - By Treatment Type
9.5.4 South and Central America Primary Biliary Cholangitis Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Primary Biliary Cholangitis Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Primary Biliary Cholangitis Market
9.5.5.1.1 Brazil Primary Biliary Cholangitis Market by Treatment Type
9.5.5.1.2 Brazil Primary Biliary Cholangitis Market by Distribution Channel
9.5.5.2 Argentina Primary Biliary Cholangitis Market
9.5.5.2.1 Argentina Primary Biliary Cholangitis Market by Treatment Type
9.5.5.2.2 Argentina Primary Biliary Cholangitis Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. PRIMARY BILIARY CHOLANGITIS MARKET, KEY COMPANY PROFILES
11.1. ZYDUS PHARMACEUTICALS, INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. TAGI PHARMA, INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. INTERCEPT PHARMACEUTICALS, INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ALLERGAN
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. AMNEAL PHARMACEUTICALS LLC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. MYLAN N.V
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. LANNETT
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. HIKMA PHARMACEUTICALS PLC
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. GEMINI PHARMACEUTICALS.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. BRISTOL-MYERS SQUIBB COMPANY
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Zydus Pharmaceuticals, Inc.
2. Tagi Pharma, Inc.
3. Intercept Pharmaceuticals, Inc.
4. ALLERGAN
5. Amneal Pharmaceuticals LLC
6. Mylan N.V
7. Lannett
8. Hikma Pharmaceuticals PLC
9. Gemini Pharmaceuticals.
10. Bristol-Myers Squibb Company